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Abstract 
This analysis is an update of last issue's article entitled “A Tale of Two Standards: 
Drift and Inertia in Modern Korean Medical Law” (SCRIPTed 5:2). After 
publication, a new Bioethics Amendment Bill (Draft 17-8353) was immediately 
introduced in Korea.  
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1. Introduction 
The law must move. It cannot be an objective, or a thing achieved. It is rather a 
journey, or a thing continually contemplated – a work in progress. It must constantly 
be in motion if it is to address the past, speak to the present, and remain relevant into 
the future. Indeed, it has been noted time and again, from the landmark ‘persons case’ 
in Canada,1 to more contemporary claims in the technology context,2 that the law 
must adapt, respond and thereby evolve, and it must not be left to stultify. The law 
simply cannot afford to stand still. And indeed the law does move and grow, albeit 
often in a reactive sort of way. 
By way of example, Korea has experienced a brief period of high turnover of ideas 
and reform proposals in the medical law field, which is undergoing a significant 
transformation in both the clinical and research settings as a result of technological 
innovations.3 However, just as it seemed a new research regime had been agreed 
through the combination of the Bioethics and Biosafety Amendment Bill4 and the 
Reproductive Cells Utilisation and Supervision Bill,5 politics intervened. These 
proposals, which had been identified by the Ministry of Health, Welfare and Family 
Affairs (MOHWFA) as legislative priorities, were abandoned when the 17th National 
Assembly was ended; and the ‘wholesale amendment’ of a legal regime that had 
failed so dramatically to curb the excesses and dishonesty of the immediately 
preceding ‘Hwang era’ was abandoned with them. 
However, as claimed above, the law cannot and does not stand still, and everyone 
knew that the Korean law governing medical research could not afford to remain 
unchanged. In place of the abandoned Bills, a new Bioethics Amendment Bill (Draft 
17-8353) was immediately introduced in Korea. Ultimately adopted and coming into 
force on 6 December 2008, Draft 17-8353 is not a new Act, but rather an Act to 
amend the existing (old) Korean Bioethics and Biosafety Act 2005 (BBA 2005).6 As 
such, the BBA 2005, albeit in amended form, retains its pre-eminent position (i.e. it 
remains the font of authority when it comes to medical research). In this short piece, 
we highlight the content of the BBA 2005, and then analyse very briefly the changes 
that Draft 17-8353 has rendered to the BBA 2005, considering whether this new 
                                                
1 Edwards v Canada (Attorney General), [1930] AC 124 (PC), a case which enunciated the ‘living tree’ 
doctrine for Canadian Constitutional interpretation, which has been fairly consistently applied and 
extended to the Canadian Charter of Rights: see Reference re s 94(2) of the BC Motor Vehicle Act, 
[1985] 2 SCR 486. 
2 See the comments of R Susskind, The Future of Law: Facing the Challenges of Information 
Technology (Oxford: OUP, 1998), or L Lessig, Code: Version 2.0 (NY: Basic Books, 2006). 
3 Recall the flurry of recent medical law reform efforts considered in S Harmon & NK Kim, “A Tale of 
Two Standards: Drift and Inertia in Modern Korean Medical Law” (2008) 5:2 SCRIPTed 267-293. 
4 Draft No. 17-7702, 6 November 2007. 
5 Draft No. 17-7703, 6 November 2007. 
6 Law No. 7150, adopted 29 January 2004, last previous amendment March 2005. 
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regime in any way alters the conclusions previously advanced in SCRIPTed with 
respect to the trajectory of medical research governance in Korea.7 
2. The Korean Bioethics and Biosafety Act 2005 and Draft 17-8353 
A function of its uneasy birth at the competing hands of the MOHFA and the Ministry 
of Science and Technology,8 the BBA 2005 pursued the dual purpose of promoting 
biotech development, on the one hand, and protecting human dignity and safety on the 
other.9 Within that overall objective, it addressed the following issues: 
• establishment of a National Bioethics Committee (NBC): ss 6-8; 
• creation of Institutional Review Boards (IRBs) by research institutions: ss 9-
10; 
• MOHWFA oversight of research institutions: ss 18-21, 38-44, and 47; 
• conduct of cloning: ss 11 and 22-23; 
• production of chimeras: s 12; 
• production of embryos, and their storage, use and disposal: ss 13-17, 20 and 
21; 
• conduct of DNA testing: ss 24-30; 
• conduct of DNA banking and protection of genetic information: ss 31-35; 
• conduct of gene therapy: ss 36-37; and 
• imposition of sanctions for breaches of the rules: ss 49-55. 
Draft 17-8353 alters or clarifies the boundaries of legal conduct with respect to 
several of these issues, and the remainder of this short article considers the old and 
new positions with respect to (1) core definitions and principles, (2) permissible 
research and conduct, (3) participant protections and (4) ethical oversight and 
enforcement. 
2.1 Core Definitions and Principles 
Although the BBA 2005 directs researchers to endeavour to safeguard human dignity 
and to carry out their work in accordance with the principles of bioethics and 
biosafety,10 it contains no explicit reference to any mid-level guiding principles, nor to 
any relevant international instruments. It does state that care must be exercised when 
storing, handling and disposing of remaining embryos, and that research must be 
halted or appropriate measures taken when research poses a significant or potential 
                                                
7 As offered in S Harmon and NK Kim, note 3. 
8 The BBA 2005 was preceded by some twelve aborted attempts by various factions within the Korean 
legislative community to introduce legislation: see S Han et al., “New Cloning Technologies and 
Bioethics Issues: The Legislative Process in Korea” (2003) 13 Eubios JAIB 216-219. 
9 See ss 1 and 4, BBA 2005, and see both S Harmon & NK Kim, note 3, and HK Kim, “Bioethics and 
Biosafety Law in Korea” (2004) 13 Journal of the Association of Policy Studies, 45-71, who argue that 
the National Assembly attached more importance to the development of biotechnology than to its 
ethical control.  
10 See s 4, BBA 2005. 
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threat to bioethics or biosafety.11 Nevertheless, there is no elucidation of the standards 
entailed by which bioethics or demanded for biosafety. Draft 17-8353 adds almost 
nothing to our understanding of the core principles or standards of bioethics in Korea, 
its only new provision being a reference to anonymisation of genetic information in 
DNA banks.12 Although this constitutes an important privacy protection, it was 
envisioned in some quarters as having the effect of vitalising the DNA bank. 
2.2 Permissible Research and Conduct 
There are three primary areas of research and conduct that are addressed in the BBA 
2005, namely embryo and reproductive research, stem cell research, and DNA 
banking. 
With respect to embryos, the BBA 2005 states that no embryo shall be produced other 
than for the purpose of pregnancy (with the consequence that no artificial 
insemination shall be undertaken for research purposes).13 However, embryos can be 
stored for up to 5 years (with the consent of the originators), after which they must be 
destroyed, unless they are to be used for research, in which case they must be pre-
primitive streak and the research must be aimed at developing contraception and 
infertility treatments, curing rare or incurable diseases as decreed by the President, or 
otherwise be approved by the President after review by the NBC.14 The BBA 2005 
clearly prohibits reproductive cloning and stipulates that no one shall conduct Somatic 
Cell Nuclear Transfer (SCNT) other than for research aimed at curing rare or 
currently incurable diseases, as decided by the President after review by the NBC.15 
Although the BBA 2005 prohibits the implantation of an animal’s somatic cell 
nucleus into a human oocyte whose nucleus has been removed,16 it does not prohibit 
the implantation of a human nucleus into an animal oocyte. Draft 17-8353 rectifies 
this lacunae, amending s 12 to now clearly prohibit nuclear transfer between humans 
and animals.17 Additionally, Draft 17-8353 redefines SCNT, limiting it to the transfer 
of a human somatic cell nucleus to a human oocyte from which the nucleus has been 
removed.18 
With respect to stem cells more specifically, both the production and importation of 
stem cell lines are permitted in Korea, and some administrative standards have been 
erected around these processes. For example, Draft 17-8353 states that those who 
                                                
11 See s 21, BBA 2005. 
12 See s 35-3(1), Draft 17-8353. By contrast, s 4 of the now abrogated Reproductive Cells Utilisation 
and Supervision Bill explicitly articulated the right of self-determination, stating that it applies to 
decisions about whether to allow reproductive cells to be extracted or donated or used to produce 
embryos. Matters of anonymisation certainly fall within the principle of self-determination, but explicit 
articulation of the underlying principle itself offers greater scope for protection insofar as it could 
support further protections and empowerments.  
13 See s 13, BBA 2005. 
14 See ss 16, 17 and 24, BBA 2005. 
15 See ss 11, 22 and 23, BBA 2005. 
16 See s 12(2), BBA 2005. 
17 Similarly, s 23 of aborted Bill 7702 also prohibited nuclear transfer between species. 
18 See s 2-4, Draft 17-8353. 
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produce or import stem cell lines must register with the Minister of Health, must 
obtain IRB approval if those stem cell lines are to be offered for research, must offer 
them free of any charge beyond the costs associated with their storage and must 
apprise the Minister of the present status of the stem cell lines (i.e. inform the 
Minister which lines are on offer at any given time).19 With respect to the research 
itself, Draft 17-8353 stipulates that stem cell research must be directed at diagnosis, 
prevention or treatment of diseases, furthering understanding of the characterisation 
and specialisation of stem cells, or some other purpose which is deemed acceptable by 
Executive Order.20 This latter provision in particular clarifies the purpose for which 
stem cell research can be undertaken, adopting broad and inclusive purposes. Finally, 
any research employing stem cells must undergo prior IRB consideration, report the 
outcome of that deliberation to the Minister of Health, submit a plan form utilising the 
stem cells to the provider of the stem cells, and must comply with the chief of the 
research institution, who is tasked with ensuring that research conforms to the 
research plans submitted.21 
Finally, as noted above, the BBA 2005 addresses the creation of DNA banks and 
Draft 17-8353 states that both local and national support will be made available for 
the management of these banks,22 though little is said about what form this support 
might take. Additionally, it states that genetic information held in banks must be 
anonymised, and the custodian of the bank must ensure the security and privacy of 
information. Further details relating to management, custody and custodial duties are 
created by Executive Order of the MOHWFA.23 
2.3 Participant Protections 
Protections for those participating in research are contained in provisions which 
address payment, consent and anonymisation of information. 
Section 13 of the BBA 2005 states that no one shall provide sperm or oocytes for the 
purpose of financial reward,24 presumably trying to avoid coercive situations 
engendered by poverty. Draft 17-8353 adds nothing to this general protective 
provision 
Section 15 of the BBA 2005 states that institutions which collect sperm or oocytes 
shall obtain written consent from donors, patients and spouses. Draft 17-8353 makes a 
number of amendments to this section with respect to egg donation procedures. First, 
it stipulates that the medical institution which produces the embryo must first perform 
a medical examination of the egg donor, and it cannot extract eggs from a woman 
whose health falls within certain criteria set by the MOHWFA.25 Second, the 
frequency of egg extractions that any single woman can undergo is to be set by 
                                                
19 See ss 20-2 and 20-3, Draft 17-8353. 
20 See s 20-4(1), Draft 17-8353, which amends s 20 of the BBA 2005. 
21 See s 20-4, Draft 17-8353. 
22 This is achieved through an amendment to s 35 of the BBA 2005. 
23 See s 35-3, Draft 17-8353. 
24 See s 13, BBA 2005. 
25 See s 15-2, Draft 17-8353. 
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Executive Order.26 Finally, the actual expenses associated with the egg donation (e.g. 
compensation for the time relating to the operation and recovery, as well as 
transportation costs) are compensable to the egg donor.27 Although these are useful 
additions, they go nowhere near as far as the provisions of the now abrogated 
Reproductive Cells Utilisation and Supervision Bill, which explicitly stated that cell 
donors (and his/her spouse) must be sufficiently informed about the potential side-
effects and consequences of extraction and/or donation, and that egg donors must be 
over 20, independent, and both physically and psychologically healthy.28 
With respect to protection of patient privacy, as noted above, Draft 17-8353 makes an 
addition to s 35 of the BBA 2005, stipulating that, in the DNA banking context, all 
collected samples and genetic information must be anonymised. Again, however, it 
does not specify how the anonymisation will be achieved, what security measure will 
be expected, whether the information could, in future, be de-anonymised, and what 
the consequences of a security failure in this respect might be. 
2.4 Ethical Oversight and Enforcement 
The BBA 2005 calls for the establishment of a National Bioethics Committee (NBC), 
which is to review matters implicating bioethics and biosafety, including policies, 
research projects on remaining embryos or involving SCNT, DNA test prohibitions, 
gene therapy target diseases, and other issues of social or moral significance 
implicated by life sciences research.29 Formed some three months after the BBA 2005 
came into force,30 it has never been clear whether the NBC is intended to be a policy 
advisory committee or a research oversight committee, and the ambiguity is not 
rectified by Draft 17-8353. 
Section 9 of the BBA 2005 calls for the establishment of IRBs. IRBs are to review all 
matters relating to (amongst other things) research undertaken by their host institute, 
including ethical and scientific validity, consent and safety measures. They must 
conduct a review where there is a serious threat or potential threat “to bioethics and 
biosafety” as a result of research. Of course, in practice, the IRBs proved utterly 
ineffective at performing their functions.31 
Draft 17-8353 recognises this and therefore includes some provisions directed at 
broadening the scope of IRB protection and enhancing the effectiveness of IRBs. For 
example, it expands the list of institutions that must seek IRB approval before they 
can act, adding embryo production institutions, somatic cell embryo clone research 
                                                
26 See s 15-3, Draft 17-8353. Note that the corresponding Executive Order has not yet been made. 
27 See s 15-4, Draft 17-8353. 
28 See ss 4 and 14, RCUSB. 
29 See s 6, BBA 2005. 
30 Pursuant to Presidential Decree No 18621, 30 December 2004. 
31 See A Han, “The Ethical and Regulatory Problems in the Stem Cell Scandal” (2007) 4 Journal of 
International Biotech Law, 45-68, and National Bioethics Committee, Intermediate Report on the 
Ethical Problems of Dr Woo Suk Hwang’s Research, 2 February 2006. 
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institutions and genetic diagnosis institutions.32 Additionally, it directs the Minister of 
Health to support the IRB framework by:33 
• providing education for IRB members; 
• establishing examinations for IRB members; and 
• enacting an evaluation system for IRBs (i.e. assessing their actions). 
The practical demands of achieving openness and of evaluating IRBs are to be 
defined and administered by Executive Orders of the Minister of Health.34 
These provisions go some way to systematising IRB function, but still do little to 
improve the independence of IRBs with respect to their host institutions (which 
proved a problem in the Hwang era). Moreover, they remain disturbingly quiet as to 
what inspectorate procedures the MOHWFA must meet, what documents it might 
regularly rely on, or what standards of conduct it will impose on IRBs in exercising its 
oversight and issuing its Executive Orders. Additionally, as noted above, they fail to 
offer or define any ethical principles which IRBs can use as a touchstone. Finally, s 
47 of the BBA 2005 remains unchanged insofar as it states that the MOHWFA may 
delegate part of its authority, including managing ERIs, to the heads of other 
institutions or to related special institutions or organisations. 
Importantly, Draft 17-8353 amends s 52 of the BBA 2005 so that its punishments – 
sentences of up to three years’ imprisonment or fines up to 30 million Korean won – 
are applicable to anyone who tempts, facilitates or mediates in providing or utilising 
sperm or eggs for monetary reward, capital gain, or other personal benefits,35 or who 
actually buys or sells sperm or eggs.36 Draft 17-8353 also makes failing to perform a 
proper medical examination of the egg donor and failing to obtain proper informed 
consent (as defined by the BBA 2005) offences subject to imprisonment of up to two 
years and/or fines up to 30 million Korean won.37 
3. Conclusion 
Readers will recall our previous conclusion that reform efforts in the Korean medical 
research setting (e.g. Bill 7702 and the Reproductive Cells Utilisation and Supervision 
Bill) represented some improvement over the old regime, but evinced a certain 
“inertia” insofar as they clung to the desire to promote biotechnology and not unduly 
hinder biotech development.38 In short, the balance achieved between biosafety 
promotion and reproductive health, on the one hand, and biotech promotion, on the 
other, remained skewed in the direction of the latter. The amendments that have now 
finally been adopted in Draft 17-8353 represent an equally modest renovation of the 
                                                
32 See s 9(1), Draft 17-8353. 
33 See s 10-2, Draft 17-8353. 
34 See s 10-2(3), Draft 17-8353. 
35 See s 51-5, Draft 17-8353, which provision already existed in the BBA 2005. 
36 See s 51-6, Draft 17-8353. 
37 See s 52-2, Draft 17-8353. 
38 For our previous conclusions on legislative activities in the medical research setting, see S Harmon 
and NK Kim, note 3. 
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regime. Obviously, the provisions directed at greater systematisation and 
improvement of IRBs, and those directed at stiffening penalties for breaches, as well 
as expanding the failures against which they can be levelled, are an improvement. 
However, there is little to encourage faith that a new research governance era has 
dawned in Korea. Much will continue to depend on the actions of the IRBs and their 
host institutions and on the MOHWFA and the content and detail of the Minister of 
Health’s Executive Orders. Of course, all of these actors failed spectacularly in their 
functions during the Hwang era – time and the generation of empirical evidence 
concerning oversight decisions will ultimately tell the tale. 
 
